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Abstract
Background: MUTYH associated polyposis (MAP) is an autosomal recessive inherited disorder.
Carriers of bi-allelic MUTYH germline mutations have a risk of approximately 60% to develop
colorectal carcinoma (CRC). In the general population about 1.5% is a heterozygous MUTYH
mutation carrier. Children of MAP patients have an increased risk of inheriting two MUTYH
mutations compared to the general population, implicating an increased risk for developing CRC.
Methods: Using data from the literature and Dutch MAP patients (n = 40), we constructed a
Markov model to perform a societal cost-utility analysis of genetic screening in MAP families.
Genetic screening was done by testing the spouse first and, in case of a heterozygous spouse, also
testing of the children.
Results: The cost of genetic screening of families of MAP patients, when compared to no genetic
screening, was estimated at €25,000 per quality-adjusted life year (QALY). The presence of Fecal
Occult Blood testing (FOBT) population screening only slightly increased this cost-utility ratio to
€25,500 per QALY. For a MUTYH heterozygote index-patient, the ratio was €51,500 per QALY.
The results of our analysis were sensitive to several of the parameters in the model, including the
cost assumed for molecular genetic testing.
Conclusion: The costs per QALY of genetic screening in families of MAP patients are acceptable
according to international standards. Therefore, genetic testing of spouses and/or children should
be discussed with and offered to counselees.
Background
MUTYH-associated polyposis (MAP), reported in 2002 by
Al Tassan et al, is the first autosomal recessive inherited dis-
order known to result in an increased risk for developing
colorectal adenomas and carcinoma [1]. Bi-allelic carriers
(with mutations in both alleles of the MUTYH gene, i.e. a
MAP patient) develop polyposis and subsequently color-
ectal carcinoma (CRC) in the majority of cases. Bi-allelic
MUTYH mutations are found in 10–25% of patients with
between 10 and a few hundred adenomas and in 1% of
Published: 2 July 2007
BMC Medical Genetics 2007, 8:42 doi:10.1186/1471-2350-8-42
Received: 9 May 2007
Accepted: 2 July 2007
This article is available from: http://www.biomedcentral.com/1471-2350/8/42
© 2007 Nielsen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2007, 8:42 http://www.biomedcentral.com/1471-2350/8/42
Page 2 of 10
(page number not for citation purposes)
patients with a colorectal carcinoma [2-4]. Patients with
more than 10 adenomas are currently being offered
MUTYH  mutation analysis. Siblings of a MAP patient
have a 25% risk of also having inherited bi-allelic muta-
tions and are eligible for genetic testing.
In contrast, the earlier identified familial adenomatous
polyposis (FAP) syndrome, caused by germline mutations
in the APC gene, is an autosomal dominant inherited dis-
ease. Carriers of one mutated APC allele develop adeno-
mas and/or CRC and their children have a 50% chance of
inheriting the disease. In these families, genetic testing is
being offered to children and other family members
because of the high probability of inheriting the disease.
In a cost comparison, it was shown that predictive genetic
testing in FAP kindreds costs less than conventional clini-
cal screening of asymptomatic family members [5].
Currently, there is discussion about testing spouses and
children of MAP patients for MUTYH mutations, since
spouses have a population risk of approximately 1–2% to
carry one (heterozygous) MUTYH mutation [1,6]. Conse-
quently, children of the affected index-patient have an
increased risk (0.5–1%) of inheriting two MUTYH muta-
tions compared to the general population (0.0025–
0.01%). An example of such a family is shown in figure 1.
The purpose of our study was to explore the economic
implications of testing the spouses for carriership and, if
the spouse is heterozygous, also their children. Bi-allelic
MUTYH children can be screened effectively using colon-
oscopies. An essential consideration involves the possible
implementation of population-wide screening. In the
near future, such a screening using Fecal Occult Blood
Testing (FOBT) from age 50 years could start in the Neth-
erlands and other European countries. In some countries,
including Germany, Austria and Japan, population-wide
FOBT-screening is already being implemented on a
national or regional scale [7,8]. In the US, adults aged 50
years or older are offered screening by means of FOBT, sig-
moidosopy or colonoscopy [9]. Because some of the gain
from genetic screening can also be obtained with FOBT
screening, we included FOBT screening as a setting in our
model.
We will present a cost-utility analysis from a societal per-
spective estimating the effect on costs and quality-
adjusted life expectancy (QALY's) of introducing genetic
testing of spouses and, if a mutation is found, the chil-
dren. We made separate analyses for: (1) the presence or
absence of population-wide FOBT screening, and (2)
whether the index patient carries one or two MUTYH
mutations.
Methods
In deciding whether to instigate genetic screening in MAP
families, the balance between societal costs and expected
health benefits should be considered. We present our
evaluation results in the terms of "additional cost per
QALY", making this a cost-utility analysis (CUA). The
model estimates effectiveness and cost per child. In our
model genetic screening is defined as genetic testing of the
spouse and, if the spouse is heterozygous, also testing of
the children. In one child families the child is tested with-
out testing the spouse first. The base case analysis is the
comparison between two strategies: genetic screening ver-
sus no genetic screening in the setting of no FOBT popu-
lation screening and for a proband with bi-allelic MUTYH
mutations. These strategies are also compared in two dif-
ferent settings: 1) presence of FOBT population screening
(between ages 50–75) and 2) for a heterozygous MUTYH
proband.
Different screening strategies were compared using a four-
state Markov model (figure 2). The model distinguishes
bi-allelic, non-bi-allelic (no or one MUTYH mutation),
and colorectal cancer (CRC) patients. Bi-allelic patients
have an increased, age-dependent CRC rate compared to
non-bi-allelic patients. Our model does not include a
detailed CRC growth and detection model because of una-
vailability of data; instead, screening was modelled by
reducing the incidence of both MUTYH-related and unre-
lated CRC (with rate λ and λmutyh, respectively) depending
on the type of screening. The baseline mortality rate is
depicted as μ and the excess CRC mortality rate as μCRC.
For a full list of assumptions for our model see table 1.
Several assumptions for the base case model were ana-
lyzed using univariate sensitivity analyses.
Families
Families were presumed to be non-consanguineous. In
the sensitivity analysis, the number of heterozygotes was
varied between 1–2%, according to the difference in fre-
quencies reported in the international literature [4,1,10,6]
The mean number of children assumed in the model was
Family pedigree showing pseudo-dominant inheritance of  MUTYH mutation(s) Figure 1
Family pedigree showing pseudo-dominant inherit-
ance of MUTYH mutation(s). Note: '4' and '11' indicate 
the number of healthy sibs.
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based on 34 Dutch MAP pedigrees with at least one child
(mean number of children 2.4, median 2).
Genetic testing
Genetic testing is performed using sequence analysis of
the coding regions of the MUTYH gene (see Nielsen [2] et
al. for details). All the pathogenic mutations reported in
the literature to date can be identified with the methods
used. In families with more than one child, testing the
spouse, rather than all the children, reduces the required
number of tests from one per child to slightly more than
one per family. Individual genetic counseling for the
spouse is not required, since in most cases he or she can
visit the clinic with the index-patient. If the spouse of an
index-patient appears to be a MUTYH mutation carrier,
the children become eligible for separate genetic coun-
seling and genetic testing.
The participation rate of the children, which influences
the total costs per child when the spouse is tested first, was
assumed to be 75%. The actual compliance rate of chil-
dren for genetic testing, when the spouse tests positive for
a MUTYH mutation, is not known. Rowley [11] reviewed
the participation rates for genetic testing in hereditary
non-polyposis colorectal carcinoma (HNPCC) family
members and found a range between 43–92%. The partic-
Model of CRC screening, in flow-diagram en decision-tree representation Figure 2
Model of CRC screening, in flow-diagram en decision-tree representation. The model distinguishes bi-allelic, non-bi-
allelic, and colorectal cancer (CRC) patients. Bi-allelic patients have an increased age-dependent CRC rate compared to non-
bi-allelic patients. Moreover, CRC patients have a higher mortality rate than non-CRC patients. Screening blocks CRC inci-
dence. Parameters: μ = General mortality rate, μCRC = Excess CRC-mortality rate, λ = Unrelated CRC-incidence, λMUTYH = 
MUTYH-related CRC-incidence, R = reduction in CRC incidence due to screening (90% for colonoscopy and 11% for FOBT 
screening)".
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ipation rate for genetic testing of children in our study was
therefore varied between 50–100%. The participation rate
of spouses was also set at 75%, based on our own data, as
most spouses (in the Netherlands) opt for genetic testing.
In the sensitivity analysis the participation rate of the
spouses was varied between 0%, when the children are
tested without testing the spouse first in all cases, and
100%.
MUTYH-related and unrelated CRC
The percentage of MAP patients reported to develop CRC
lies between 50–70% of cases [2,4,10]. The age of diagno-
sis of CRC in MAP patients was based on the age distribu-
tion among 73 MAP patients with CRC, as previously
published [2]. The phenotypical expression of the disease
is not yet fully established. Until now, 7,949 healthy sub-
jects have been tested for MUTYH  mutations [12] and
although no bi-allelic mutation carriers were found, there
is still a possibility that some bi-allelic MUTYH mutation
carriers will not develop polyps and carcinoma. Hence, the
penetrance of CRC in MAP patients was varied between
40–70% in the sensitivity analysis.
In 2003, the cumulative risk for 0–79 years for CRC in the
general Dutch population was 6% (Association of Com-
prehensive Cancer Centres, ACCC). For the survival of
CRC patients we used data from the ACCC [13]. These
data were modelled using a so-called cure model [14] in
which 52% of patients is cured without excess mortality
and the remaining 48% have a constant excess mortality
rate of 0.49 per year.
The natural history of CRC in MAP patients may differ
from that in the general population. It is possible that
Table 1: Cost-effectiveness model: input variables and sources
Variable Base case Assumption 
(costs indexed at 2006)
Range Source
Prevalence of MUTYH mutations in population 1.5% 1–2% Al Tassan 2002, Croituro 2004, own data 
(unpublished) [1;6]
Prevalence of CRC in MAP patients 60% 40–70% Nielsen 2005, Sampson 2003, Gismondi 
2004 [2–4]
Mean age of diagnosis of CRC in MAP patients 49 year Nielsen 2005, Sampson 2003, Gismondi 
2004 [2–4]
Baseline cure rate in MAP patients after CRC 52% 30–60% IKA/Association of Comprehensive Cancer 
Centers, [13]
Mean number of children per family 2 children 40 Dutch MAP patients (own data, 
unpublished)
Life expectancy after CRC Table* IKA/Association of Comprehensive Cancer 
Centers, [13]
Life expectancy total population Table* Central Bureau of Statistics (Statistics 
Netherlands), [32]
Utility after CRC 0.90 0.85–0.95 [24]- utility 9 month after surgery- mean 
[22] [23]
Spouses compliance to testing 75% 0–100% See methods, own data, Rowley 2004 [11]
Childrens' compliance to testing 75% 50–100% Rowley 2004 [11]
Age start screening children 25 year 20–25 year See text
CRC costs 50–200% van den Brink 2004 [24]
• initial treatment and recurrence 21,330
• continuing care 2130/year
• non-health care (productivity) 11,060
Costs of genetic testing in a DNA diagnostic 
laboratory social costs (travel/production)
645€
95€
200–1000€ Costs genetic testing Leiden University 
Medical Center (LUMC) [25]
Colonoscopy costs (including polypectomy and 
complications)
561€ (480€ + 81€) LUMC, Heitman 2005 [18]
Social costs (travel/production) 70€ Oostenbrink 2004 [25]
Effectiveness colonoscopy (reduction in CRC cases) 90% 70–80% Winawer 1993 [16]
Effectiveness FOBT (reduction in mortality) 11% 10–30% Kronborg 2004 [19] Faivre 2004 [20]
FOBT 65€ (18€ medical & 47€ time) Gyrd-Hansen 1998, Oostenbrink 2004 [7] 
[25]
Discount rate 4% 3–5% Oostenbrink 2004 [25]
* Extensive tables, please contact corresponding author for detailed information.BMC Medical Genetics 2007, 8:42 http://www.biomedcentral.com/1471-2350/8/42
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MUTYH-related CRC patients may have a better survival
than sporadic CRC cases, as reported previously in
HNPCC patients [15], or worse survival. Therefore, the
52% baseline cure rate in MAP patients after CRC diagno-
sis was varied in the sensitivity analysis between 0.30 and
0.60.
Colorectal colonic screening
Winawer et al. reported that the incidence of CRC was
reduced by 90% in patients that had one or more, large (>
1 cm) adenomas removed when periodic colonoscopy
and polypectomy were performed [16]. MAP patients
have between 10–500 adenomas at a mean age of 50
years, and are apparently not comparable to the standard
symptomatic patient (e.g. with rectal blood loss) in whom
usually less than ten adenomas are detected at colonos-
copy. However, the number of polyps in the MAP patients
accumulates over time and, if screening is started from
young adulthood, the number of adenomas encountered
every two years is expected to be considerably lower.
Besides our base case assumption of a 90% reduction, we
also included a 70% and 80% reduction in CRC in the
sensitivity analysis. The optimal interval between colono-
scopies for those at highest risk seems to be two years [17].
Two-yearly colonic screening in our model started at age
25 and ended at 79 years. At the present time, MAP
patients are advised to have screening from age 25 years
[2], in a sensitivity analysis we set the start of colonic
screening also at age 20. The effect of colonic screening
was modeled by uniformly reducing the incidence of
MUTYH-related and unrelated CRC, resulting in an equal
reduction in mortality. Except in the costs, the conse-
quence of changing the interval between colonoscopies
was not explicitly incorporated in the model.
The risk of bleeding and perforation per colonoscopy was
assumed to be 0.5–0.24%, respectively, based on a recent
article by Heitman et al. Mortality after a perforation was
reported to be 4.7% [18].
Population-wide screening
To incorporate population-wide screening in our model,
we used the most recently published figures from a large
prospective study in Denmark, 'the Funen study', in which
biennial screening with (unhydrated) FOBT was used. A
significant reduction in mortality of 11% in the screened
group was reported after a study period of 17 years,
including nine rounds of FOBT. This figure increased to
12% in persons participating in all nine rounds. The better
survival rate is the result of detecting the CRC earlier; there
was no reduction in the total number of colorectal cancers
[19]. Others have found a 16% mortality reduction over
an 11 year period, using also (unhydrated) FOBT [20].
Also population-wide screening could well become more
effective in the future because of refinements in FOBT
and/or other screening techniques [21]. Besides the base
case 11% reduction for population-wide screening, we
therefore included a 20% mortality reduction in the sen-
sitivity analysis.
Quality-adjusted life years
Quality-adjusted life years (QALYs) are often used as an
effectiveness measure for health-economic evaluations,
because they capture both length and quality of life, and
can therefore be used to compare a wide variety of dis-
eases and treatments. To adjust for the quality of life, a
utility factor is used on a scale from one (perfect health)
to zero (as bad as death). In the case of CRC, quality of life
can be impaired because of physical discomfort after sur-
gery or the need to carry a stoma, for example. Utility fac-
tors reported in the literature vary between 0.83 [22] and
0.981 [23] due to differences in measuring instruments
and the length of follow up. In our base case analysis we
used a utility factor of 0.90 after incidence of CRC, based
on a report by Van den Brink et al [24]. In the sensitivity
analysis the utility factor was varied between 0.85 and
0.95.
Costs
We analyzed the costs from a societal perspective, so
besides medical costs, the model also included health-
related non-medical costs, including loss of productivity
and patients' time and travel costs associated with health
care. Only MUTYH- and CRC-related costs were included
in the model. Costs were expressed in euros, indexed to
2006 prices.
The costs for genetic testing of the MUTYH gene are low
compared to other genes, because the gene is relatively
small (11.4 kb) and the analysis is not complicated. The
standard charge for molecular genetic testing at our DNA
laboratory in the LUMC in Leiden is €645. This includes
the costs for the actual DNA test, labor time and adminis-
trative costs. We added patients' time and travel costs of
€95 [25], leading to our base case overall cost estimate of
€740 per genetic test. This was varied between €200 and
€1000 in the sensitivity analysis. The charge for genetic
counseling of children of MAP patients was set at €144,
which is the rate for testing family members at our clinic.
Costs associated with CRC were based on a large Dutch
study for evaluating the cost-utility of pre-operative radio-
therapy in rectal cancer patients undergoing surgery [24],
which reported mean total costs of €110,100 (indexed at
2002) per patient. Based on these data we set costs at
€21,330 for initial treatment and €2,130 per year for con-
tinuing care (indexed at 2006). The costs of loss of pro-
ductivity after CRC diagnosis were estimated at €11,060
per CRC diagnosis, based on the friction costs method
[26]. We used these costs from rectal cancer patientsBMC Medical Genetics 2007, 8:42 http://www.biomedcentral.com/1471-2350/8/42
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because they were comprehensive and presented in a way
that facilitated the use in our model structure. Other pub-
lications reported only total costs [27], from which it
would not be easy to derive initial costs and annual costs.
Moreover, the cost data we used were not inconsistent
with the widely variable data reported for CRC patients in
general. Because of possibly different costs for colorectal
than for rectal cancer patients and the large differences
reported in the international literature [18] we varied the
total costs per CRC diagnosis by 50–200% in the sensitiv-
ity analysis.
Costs for colonoscopy at our clinic are €474 and time and
travel were estimated at €70 [25] (indexed at 2006). The
costs per bleeding and perforation were assumed to be
€3,067 and €29,982, respectively [28].
The costs for population-wide FOBT screening were
obtained from the cost-effectiveness analysis by Gyrd-
Hansen et al in 1998, based on the outcomes of the
"Funen trial" [29]. In this study different strategies were
postulated, we used the data from strategy C in table 1
because in this strategy screening starts from age 55 years
and is repeated every 2 years, which is most similar to that
advised by the EU council (screening between ages 50–
75) [30,31]. Their estimated cost-effectiveness of €4,400
per life-year-saved was reconstructed in our own model by
assuming medical costs at €18 per individual FOBT. In
addition, time and travel costs were assumed to be €47
[25].
Miscellaneous
Based on data from the Dutch national statistic bureau in
2005, the life expectancy of the general population at
birth is set at 77.0 and 81.5 years for men and women,
respectively [32]. The Markov model used a life-long time
horizon, divided into one-year cycle times and truncated
at age 100. Future cost and quality-adjusted life years were
discounted at 4%, as advised in Dutch guidelines for eco-
nomic health care evaluations [25]. We varied the dis-
count rate between 3–5% in our sensitivity analysis. For a
full list of assumptions for our model see table 1.
Results
Table 2 shows the results of the base case analyses. The
expected health gain per bi-allelic child was estimated at
2.4 quality-adjusted life years, which is seven quality-
adjusted days per screened child. With costs amounting to
€470 per screened child, the estimated cost-utility ratio is
€25,000 per QALY. In the presence of FOBT screening, the
incremental cost of genetic screening -in persons that also
will be invited in population screening- increases only
slightly to €25,500 per QALY. If the index patient is a het-
erozygote, the costs per QALY are €51,500 (and €52,500
if population screening is introduced, results not shown).
See table 2 for the estimated costs per life year (LY) gained.
Sensitivity analyses
The sensitivity analyses (figure 3) showed a considerable
variation in possible costs per QALY. The factors dominat-
ing the cost-effectiveness analysis were the percentage of
heterozygotes (€18,500–38,000 per QALY), percentage of
MAP patients that develop CRC (€21,000–38,500 per
QALY), mortality due to MAP-related CRC (€20,500–
37,000 per QALY), cost of genetic testing (€9,000–37,500
per QALY), compliance of spouses (€20,000–40,000 per
QALY), effectiveness of colonoscopy (€29,500–35,500
per QALY) and discount rate (€17,500–35,000 per
QALY). Varying the CRC costs, compliance rate of chil-
dren, utility rate, starting age for screening, and the effec-
tiveness of population-wide screening influenced the cost-
effectiveness ratio by less than €4000 per QALY.
Discussion
A cost-utility analysis, relating costs to the gain in QALYs,
is generally accepted as an valuable tool for medical deci-
sion-making [33,34]. Since economic considerations are
never the only decision criterion, it is impossible to set a
Table 2: Results of cost-effectiveness (CE) analyses: incremental effect of genetic screening of MAP families compared to no genetic 
screening, in different settings:
Base case With FOBT* Heterozygote MUTYH indexpatient
Results per child
- Additional costs €470 €470 €469
- QALY# gain, discounted 0.018 years (7 days) 0.017 years (6 days) 0.009 years (3 days)
Results per bi-allelic child
- Additional costs €58,500 €59,000 €120,500
- LY† gain, undiscounted 6.9 years 6.7 years 6.9 years
- LY gain, discounted 1.4 years 1.4 years 1.4 years
- QALY gain, discounted 2.4 years 2.3 years 2.4 years
Cost effectiveness (in €/LY undiscounted) 8,500 9,000 17,500
Cost effectiveness (in €/LY discounted) 42,000 42,000 86,500
Cost effectiveness (in €/QALY discounted) 25,000 25,500 51,500
*FOBT: Population screening using Fecal Occult Blood Testing, †LY: Life years, #QALY: Quality-Adjusted Life YearBMC Medical Genetics 2007, 8:42 http://www.biomedcentral.com/1471-2350/8/42
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strict threshold for the acceptable costs per QALY. A rule
of thumb, which is often quoted in the literature, is that
costs up to US $20,000 per QALY are certainly acceptable,
up to US $50,000 per QALY are probably acceptable, and
up to US $100,000 might be acceptable [35,36]. Others
have advocated higher thresholds of up to US $200,000
per QALY [37]. Threshold values in terms of Euros would
be somewhat higher, since dollars are more valuable than
euros (purchasing power parity US $1 = €1.12, [38], June
2006). The Dutch have recently proposed a threshold of
€80,000 per QALY [39].
Since the discovery of the MUTYH gene in 2002, hundreds
of patients have been diagnosed with MUTYH-associated
polyposis. The outcome of our cost-utility analysis shows
that genetic testing in MAP families has an acceptable
costs per QALY ratio, also after FOBT population-wide
screening is introduced (€25,000 and 25,500 per QALY,
respectively). The benefit in terms of discounted QALYs
per child is seven days per child. This might seem insignif-
icant, but for a child with bi-allelic MUTYH mutations this
implies a survival benefit of 2.4 quality-adjusted life years
and 6.9 undiscounted life years (table 2). Testing the fam-
ily of MUTYH heterozygotes, with an estimated cost-
utiltiy ratio of €51,500 per QALY, might also be accepta-
ble according to national and international standards,
which opens the possibility of cascade screening.
The major limitation of our model is the availability of
representative and reliable data. Using univariate (one-
way) sensitivity analyses, the consequences of varying dif-
ferent major inputs of the model were investigated. If a
spouse does not participate in testing and the children are
tested first, the costs increase to €40,000 per QALY. All
other key variables led to cost-utility ratios that were more
favorable than €40,000 per QALY.
Apart from the availability of reliable data our study has a
number of further limitations. First, we did not include
the occurrence of duodenal adenomas and duodenal can-
Sensitivity analyses Figure 3
Sensitivity analyses.
Abbreviations: CRC=colorectal cancer; FOBT= Fecal Occult Blood Testing, CE= cost-effectiveness QALY= quality adjusted life year
Cost-effectiveness ratio in €/QALY
Base Case Analysis (25,000 €/QALY)
    
1  MUTYH  heterozygotes in       2%
 population  (1,5%)  1%
2 MUTYH  related  CRC    70%
 (60%)  40%
3  Cure rate MUTYH CRC  60%
 (52%)  30%
4 CRC  costs    200%
 (32360  +  2130/year)  50%
5  Costs genetic testing   200€ 
 (645)  1000€ 
6 Compliance  children    100%
 (75%)  50%
7 Compliance  spouses  100%
 (75%)  0%
8  Utility after CRC   0,85  
 (0,90)  0,95 
9  Age children at start   20yr 
  colonic sccreening (25)  25yr 
10  Effectiveness colonoscopy   80%
 (90%)  70%
11 Discount  rate  3%
 (4%)  5%
12 Reduction  mortality  FOBT  10%
(0%) 20%
0,000 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000BMC Medical Genetics 2007, 8:42 http://www.biomedcentral.com/1471-2350/8/42
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cer which has been reported in a few MAP cases [40] and
which is likely to improve the cost-effectiveness of genetic
testing in MAP families. At present, there is not enough
information to include this in our cost-effectiveness anal-
ysis. MAP patients are currently advised to undergo upper
gastro-intestinal tract screening once every 1–5 years,
depending on the findings of the previous endoscopy.
Second, patients carrying a heterozygous MUTYH muta-
tion might also have a slightly elevated risk for developing
CRC. Jenkins et al (2006) found a three-fold relative risk
for colorectal cancer in MUTYH heterozygotes in a popu-
lation-wide case-family study [41]. In contrast a recent
meta-analysis of case controls studies showed a non-sig-
nificant RR of 1,3 (O,99–1,55 for heterozygote MUTYH
carriers [12].
Colonoscopic screening of MUTYH heterozygotes from
the age of 50 is probably cost-effective, as this was also the
case for the general population [27]. Third, although
genetic testing is evidently more efficient in larger fami-
lies, we did not stratify the cost per QALY for the actual
number of children in a pedigree. In our opinion, once
such genetic testing has been established as a standard
procedure, it would be ethically unacceptable in clinical
practice to withhold it from smaller families; especially
since the participation and number of children only influ-
ences the costs per child, not the estimated effectiveness
per child who tests positive. Fourth, we did not include
the psychosocial aspects of genetic counseling in our anal-
ysis. People may experience changes in their functional,
emotional or social status after learning their genetic pre-
disposition. These responses, before and after genetic test-
ing, have been characterized in patients at risk for
Huntington's disease and inheritable breast cancer
[42,43]. Potential adverse effects depend on the severity of
the disease in question. We consider these effects to be less
for MAP than Huntington or inheritable breast cancer,
because the existence of a pre-cancerous stage (adenomas)
makes it possible to detect and prevent colorectal cancer
by regular colonic screening. Griffith et al. stated that a
cost-utility analysis is not suitable to account for the
impact of genetic services on the individual, the family
and society because of difficulties in measuring non-
health benefits. There is a need for further research on the
psychosocial impact of genetic services within a health-
economics context [44]. For now, we recommend that
counselors should consider the psychosocial implications
for anyone tested for MUTYH mutations as much as in
any other genetic counseling procedure. Fifth, our model
is inadequate to evaluate the cost-effectiveness of FOBT
screening. For that purpose, more sophisticated models
are required and available [29,45]. The data requirements
of these models prevent their application to the evalua-
tion of genetic screening. We did included FOBT screening
as a setting in our model, because some of the gain from
genetic screening can also be obtained with FOBT screen-
ing. Therefore, the presence of FOBT screening reduced
the gain from genetic screening, but only to a very limited
extent. And finally, we did not consider alternative popu-
lation-wide screening techniques such as colonoscopy
and sigmoidoscopy. These screening endoscopies are
respectively offered once per 10 and 5 years, in places
where these have been introduced, which is probably not
frequent enough for MAP patients because they develop
tumors in shorter periods.
Conclusion
Despite several limitations, our model shows that the
costs per QALY of genetic screening in families of MAP
patients are acceptable according to international stand-
ards and we therefore recommend that genetic screening
should be discussed with and offered to MAP families in
clinical genetic practice.
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Appendix
Word explanation: bi-allelic = two (i.e. homozygous or
compound heterozygous) MUTYH mutations; a heterozy-
gote/heterozygous mutation = one MUTYH mutation;
non-bi-alellic = no (a non-carrier) or one MUTYH muta-
tion (a heterozygote); proband or indexpatient = the
affected subject who led to the research done on their fam-
ily
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